Kornimate/medical-research-clean huggingface dataset:
catheter ablation versus antiarrythmic drugs for atrial fibrillation in china

Conditions: Atrial Fibrillation

Summary: the mainstay of treatment for atrial fibrillation remains pharmacological;however,catheter ablation has increasingly been used over the last decades. the relative merits of each strategy have not been extensively studied. our study was designed to determine if catheter ablation is a feasible option as first-line therapy for treating patients with symptomatic af.


Eligibility criteria:
inclusion criteria: * 1 patients with symptomatic af recorded by ecg or holter 2 age:18-75 years 3 patients who are willing to enroll in the trial exclusion criteria: * 1 patients accompanied hyperthyroidism 2 patients with sever liver or renal dysfunction 3 patients with sever cardiac dysfunction 4 patients had previous radiofrequency catheter ablation in the la or maze surgical procedure 5 patients with emboli in atrium 6 pregnant woman
feasibility clinical study of the alma system in treating primary postpartum hemorrhage

Conditions: Postpartum Haemorrhage (PPH); PPH; Postpartum Hemorrhage (Primary)

Summary: feasibility clinical study of the alma system in treating primary postpartum hemorrhage (pph).

10 subjects, first in woman trial with ethics committee oversight. women who experienced postpartum hemorrhage will be treated with the alma system, which aims to rapidly reduce or stop the bleeding by targeting the primary cause: uterine atony. the primary objective is to verify the safety of the alma system in humans by: 1. ensuring the absence of serious adverse events (saes) related to the use of the alma system during and after the procedure. 2. evaluating any observable damage to the uterus, cervix, or vagina due to the use of the alma system. 3. evaluating the occurrence of uterine inversion or folding during the use of the alma system. the secondary objectives include evaluating: 1. the ability to easily place the alma system trans-vaginally. 2. the ability to connect the alma system to a vacuum source and maintain the desired negative pressure. 3. the ability of the alma system to contract the uterus to a level that reduces or stops blood loss and avoids further non-surgical and surgical intervention. 4. the time from insertion and start of negative pressure to a visible reduction in blood loss.

Eligibility criteria:
inclusion criteria: 1. adult female, 18 years of age or older at time of consent. 2. subject or her legally authorized representative is able to understand and provide consent to participate in the clinical investigation. 3. subjects who present with an atonic uterus for at least 10 minutes after expulsion of placenta with failure to obtain contraction and/or subjects who have lost blood post-vaginal delivery \> = 500 ml and lost blood post-cesarian delivery \> = 1000 ml and according to the investigator's judgment, require an intervention. 4. failed first-line intervention of uterotonics and uterine massage/bimanual uterine massage to stop bleeding. exclusion criteria: 1. subjects who do not provide informed consent to participate in the clinical investigation. 2. subjects who deliver at a uterus size \< 34 weeks. 3. subjects who have lost \> 1000 ml of blood for vaginal birth and \> 2000 ml for caesarian delivery. 4. subjects who have abnormal pt, ptt and inr. 5. subjects who present with retained placenta, uterine lacerations, or for any other conditions outside of atonic post-partum hemorrhage. 6. pph that the investigator determines to require more aggressive treatment, including any of the following: * hysterectomy; * b-lynch suture; * uterine artery embolization or ligation; * hypogastric ligation; * known uterine anomaly; * ongoing intrauterine pregnancy. 7. placental abnormality including any of the following: * known placenta accreta; * retained placenta with known risk factors for placenta accreta (e.g., history of prior uterine surgery, including prior c-section and placenta previa); * retained placenta without easy manual removal. 8. known uterine rupture 9. unresolved uterine inversion.

Keywords: alma system postpartum hemorrhage pph
benefit of ethanol sclerotherapy of endometriomas before ovarian stimulation on pregnancy rates in ivf/icsi

Conditions: Infertile Women Undergoing IVF or ICSI

Summary: evaluation of progressive pregnancy rates (with an embryo with cardiac activity at 12 weeks), on a first attempt at ivf/icsi (fresh and frozen embryo transfers) following the discovery of one or two endometrioma(s) of 30 to 80 mm, without a history of cystectomy, and comparison between the two groups: ethanol sclerotherapy and therapeutic abstention


Eligibility criteria:
inclusion criteria: * infertile women aged 18 to 43, * presenting one or 2 endometriotic cysts of 30 mm to 80 mm long axis, confirmed by ultrasound and/or pelvic mri and without signs of atypia, * with indication of ivf/icsi, first ivf/icsi after the discovery of endometriosis cyst(s), * having given their consent. exclusion criteria: * a history of ovarian cystectomy, * a non-homogeneous cyst that cannot be punctured (risk of incomplete aspiration), * complex adnexal image that cannot exclude an associated hematosalpinx (communicating hematosalpinx, tissue component), * a recent tubo-ovarian infection, * an active, untreated vaginal infection, * anticoagulant treatment at a therapeutic dose, * all adult patients protected by law (under guardianship or curatorship), * problems understanding the french language, * participation in intervention research, * all patients not affiliated to the social security system.
biological standarization of cupressus arizonica allergen extract to determine the biological activity in histamine equivalent units (hep)

Conditions: Allergy to Tree Pollen

Summary: biological standardization of cupressus arizonica allergen extract.

this is an open, unblinded and non-randomized biological assay. the study design is a slight modification of the recommendations proposed by the nordic guidelines.

Eligibility criteria:
inclusion criteria: * subject has provided written informed consent, appropriately signed and dated by subject. * subject can be male or female of any race and ethinic group. * age 18 years and 60 years ata the study inclusión day. * positive clinical history of inhalatory allergy to cupressus arizonica. * a positive prick test with a standarices commercially cupressus arizonica allergen extract. * a positive prick test with positive control of histamine 10 mg/ml. * a positive test for specific ige to cupressus arizonica. exclusion criteria: * immunotherapy in the past 5 years with an allergen extract cupressus arizonca or other allergen extract than may interfere with the allergene to be tested. * use of drugs that may interfere before and after with the skin reactions. * treatment with certain drugs.

Keywords: allergy to cupressus pollen
revitalization of traumatized immature permanent teeth

Conditions: Apical Periodontitis; Trauma

Summary: this study aims to assess the hypothesis that revitalization of teeth without (a)symptomatic apical periodontitis have a more favourable outcome in terms of further root development, periapical bone healing, maintaining/regaining pulp sensitivity and survival, than teeth with (a)symptomatic apical periodontitis.

1. trial objectives this study aims to investigate the effectiveness of revitalization procedures, in terms of maintaining or restoring periapical health, further root development and regaining of pulp sensitivity, in immature permanent teeth with (group 1) or without (group 2) (a)symptomatic apical periodontitis . 2. primary endpoints rra at 1 year post revitalization. 3 secondary endpoints maintained or restored periapical health (evaluated within each group separately due to expected baseline inequivalency between groups) 1 year post revitalization. 4 other endpoints * rra 2 and 3 years post revitalization * maintained or restored periapical health 2 and 3 years post revitalization (evaluated within each group separately) * pulp sensitivity 1-3 years post revitalization (evaluated within each group separately due to expected baseline inequivalency between groups) * tooth survival 3 years post revitalization (even if no further root development and incomplete periapical bone healing with no clinical symptoms). 5 trial design open, prospective cohort, multicenter blinded: radiographic assessment and statistical analysis; operators and patients cannot be blinded, due to practically not feasible.

Eligibility criteria:
inclusion criteria: * provision of informed consent * female and male patients * age range: 6-18 years * "healthy": asa i and ii * permanent immature tooth (cvek stage of root maturation ≤ 2) requiring revitalization * etiological factor: (a)symptomatic apical periodontitis post dental trauma or irreversible pulpitis post dental trauma exclusion criteria: * unlikely to be able to comply with the study procedures, as judged by the investigator * patients older than 18 years and younger than 6 * deciduous teeth * cvek root maturation stage \> 2: permanent immature tooth that can be treated by conventional root canal treatment or apexification * known or suspected current malignancy * history of chemotherapy within 5 years prior to study * history of radiation in the head and neck region * history of other metabolic bone diseases * bleeding disorders * involvement in the planning and conduct of the study
participation restrictions in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: objective: to evaluate what factors contribute to social participation restrictions in subjects with rheumatoid arthritis (ra), considering the model international classification of functioning (icf). methods: cross-sectional study with 81 individuals with rheumatoid arthritis, using instruments to measure two constructs of component social participation.

in this study the definition of social participation considered several areas, such as marriage and family, work, leisure, religion, economy, and politics which are based in the social scales of the questionnaires sf-36 and aims2.

Eligibility criteria:
inclusion criteria: * age greater than 18 years of age * mental capacity as assessed by the brazilian version of mini mental state examination * diagnosis of ra according to the american college of rheumatology (acr) 1987 criteria established by attending service rheumatologist. exclusion criteria: * individuals who had undergone surgery of the upper limbs, were unable to comply with the protocol for data collection, or with non-corrected visual deficits that could interfere with their functionality were excluded

Keywords: social participation international classification of functioning
flu-like symptoms as a complication of botulinum toxin therapy

Conditions: Flu-like Symptoms

Summary: botulinum toxin (bont) has become a revolutionary treatment for many neurological, autonomic, gastrointestinal, genitourinary, and cosmetic disorders. the use of this treatment requires expertise in dosage calculations and application technique to avoid potential side effects. most adverse events (aes) related to bont are local and related to its mechanism of action, i.e., paralysis of unwanted muscles. however, systemic aes may also be observed. flu-like symptoms (fls) are well recognized aes in patients treated with bont; however there is a paucity of information regarding the frequency, clinical impact, and associated risk factors of this particular complication. between december 1989 and may 2003, 1,437 reports of bont-related aes were registered at the food and drug administration (fda). fls were reported in 4.6% of serious, and 3.2% of non-serious side effects. in this study, the investigators aim to assess prospectively the frequency, clinical characteristics, and risk factors for development of fls in a group of patients affected with diverse movement disorders and treated with bont type a at the parkinson's disease center and movement disorders clinic (pdcmdc) of baylor college of medicine (bcm). the investigators will also assess biomarker of inflammatory response in those patients who develop fls after treatment with bont.


Eligibility criteria:
inclusion criteria: 1. patients with any movement disorder: dystonia, tremor, tics, myoclonus or tardive dyskinesias and treated with botulinum toxin type a (botox or dysport) to type b (myobloc) 2. patients who will be injected in at least two consecutive visits in our clinic, three months apart. 3. we will invite patients who are regularly treated in our clinic "established patients" and those who will be treated for the first time "new patients". 4. patients who are willing to complete with the study requirements. 5. patients who deny the blood sample will be included for the symptoms and risk factors analysis. 6. patients who give written informed consent. exclusion criteria: 1. patients who will only be injected with bont once in our clinic at bcm. 2. patients who deny participating in the clinical survey.

Keywords: botulinum toxin flu like symptoms frequency of fls botox
to evaluate the efficacy and safety of rapamycin for crohn's disease-related stricture

Conditions: Crohn's Diseases

Summary: crohn's disease （cd） with stenosis has limited therapeutic options and with high surgical rate. the present clinical trial aims to evaluate the efficacy and safety of rapamycin in the treatment of stricturing crohn's disease.

management of crohn's disease （cd） with stenosis is challenging and often requires endoscopic dilatation or surgical resection of the strictured bowel. sirolimus (rapamycin), a macrocyclic antibiotic with immunosuppressive and antineoplastic properties, has been reported as promising rescue therapy for refractory cd. this study aims to evaluate the use of sirolimus for stricturing crohn's disease. patients in this study will receive a continuous dosing schedule of oral sirolimus 2mg daily for six months. clinical responses were defined as the ability to tolerate the regular diet with vegetable fiber combined with a reduction of ≥ 75% in overall target score and a score of less than two points for each item.

Eligibility criteria:
inclusion criteria: 1. chinese patients (≥18 years of age) with a documented definite diagnosis of cd; 2. the presence of a clinically symptomatic stricture; 3. strictures confirmed by endoscopy (passage of the endoscope with resistance or not traversable) or imaging (ct enterography (cte) or mr enterography (mre). exclusion criteria: 1. patients who were pregnant, diagnosed with intestinal perforation, complete intestinal obstruction, any signs of dysplasia or malignancy, or use of anti-tumor necrosis factor (tnf) in the last three months; 2. patients who were not followed up between the inception of medication and any other subsequent treatments.

Keywords: rapamycin stricture fibrosis
pemetrexed plus cisplatin versus gemcitabine plus cisplatin for advanced nsclc metastatic non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer; Efficacy

Summary: a phase iii trial has demonstrated that in advanced non-small cell lung cancer (nsclc) cisplatin/ pemetrexed provides similar efficacy with better tolerability and more convenient administration than cisplatin/gemcitabine. moreover,this trial showed survival differences based on histologic type. the investigators want to research some biomarkers that can predict clinical outcomes.


Eligibility criteria:
inclusion criteria: 1. chemotherapy-naive patients with histologically or cytologically confirmed adenocarcinoma and large-cell carcinoma, classified as stage iiib not amenable to curative treatment or stage iv 2. with at least one unidimensionally measurable lesion according to the response evaluation criteria in solid tumors; 3. with an eastern cooperativeoncology group performance status of 0 or 1, 4. at least 18 years of age 5. adequate bone marrow reserve and organ function including calculated creatinine clearance 45 ml/min based on the standard cockcroft and gault formula. 6. prior radiation therapy was permitted if it was completed at least 4 weeks before study treatment 7. patients had fully recovered from its acute effects. exclusion criteria: 1. peripheral neuropathy \> national cancer institute common toxicity criteria grade 1 2. progressive brain metastases, 3. uncontrolled third-space fluid retention before study entry. 4. patients unable to interrupt aspirin and other nonsteroidal anti-inflammatory drugs or if they were unable or unwilling to take folic acid, vitamin b12, or corticosteroids.
comparison of platelet rich plasma and alternative therapies for the treatment of tennis elbow (lateral epicondylitis)

Conditions: Lateral Epicondylitis (Tennis Elbow)

Summary: "tennis elbow" is the most common cause of lateral elbow pain, generally caused by either work or sports related repetitive strain. in this condition, a tendon along the outside of the elbow becomes inflamed leading to pain, especially with flexing and extending the elbow. many treatments have been attempted, including physiotherapy and steroids, with little success. one treatment which has been very effective is the injection of the patients own blood (taken from their other non-affected arm) into their abnormal tendon. the blood recruits the patients own healing factors and heals the damaged tendon. as platelets are thought to be largely responsible, injection of concentrated platelets, extracted from the patient's blood (platelet rich plasma) is a newer, but expensive, technique. at this point, it is unclear whether whole blood, concentrated platelets, or simply passing a ultrasound-guided needle through the abnormal tendon as a means to stimulate tissue healing (tendon fenestration) is the better treatment. the objective of this trial is to compare platelet rich plasma, whole blood, dry needle tendon fenestration, and sham injection (with physical therapy) to identify the best and most cost-effective therapy for this debilitating condition.


Eligibility criteria:
inclusion criteria: * adult man or woman aged 18 years or greater. * clinical diagnosis of lateral epicondylitis based on site of pain, pain elicited with active extension of the wrist in pronation and elbow extension. * documented sonographic diagnosis of common extensor tendinosis based on tendon thickening, areas of hypoechogenicity, and loss of the normal echotexture. * chronic symptoms (equal or greater than 3 months). * pain of at least 5 out of 10 on a visual analog scale (vas). * provision of informed consent. exclusion criteria: * acute symptom onset (less than 2 months). * history of acute elbow trauma (less than one week). * history of rheumatoid arthritis. * history of malignancy. * pregnancy * patients requiring anti-platelet medication for the treatment of heart attack, stroke or other medical condition. * previous surgery for lateral epicondylitis. * previous local injections, including steroids within the past 6 months. * signs of other causes for lateral elbow pain (posterior interosseous nerve entrapment, osteochondral lesion).

Keywords: lateral epicondylitis tennis elbow platelet rich plasma whole blood tendon fenestration
coronary angiography before elective carotid endarterectomy in patients with asymptomatic coronary artery disease

Conditions: Carotid Stenosis; Coronary Stenosis

Summary: the purpose of this study is to evaluate the potential benefit of systematic preoperative coronary angiography followed by selective coronary artery revascularization on the incidence of myocardial infarction (mi) in patients without a history of coronary artery disease (cad) and undergoing carotid endarterectomy (cea).

patients candidates for cea, with no history of cad, a normal electrocardiogram (ecg), and a normal cardiac ultrasound were randomized in two groups. in group a (n = 216) all patients underwent coronary angiography before cea +- coronary artery revascularization. in group b (n = 210) cea was performed without coronary angiography.

Eligibility criteria:
inclusion criteria: * indication for carotid endarterectomy * no clinical sign or history of ischemic heart disease * no electrical signs of cardiac ischemia * left ventricular ejection fraction \>50% at transthoracic echocardiogram. exclusion criteria: * disabling stroke (mrs ≥3) * non atherosclerotic carotid disease * severe intracranial carotid artery stenosis * contra-indications to heparin, aspirin or clopidogrel.
sglt2-inhibitors on pc-aki

Conditions: Impact of SGLT2-inhibitors on PC-AKI in ACS Patients Receiving Invasive Strategy

Summary: percutaneous coronary intervention (pci) is one of the most common invasive strategies employed in the diagnosis and treatment of coronary artery disease (cad) patients. invasive procedures necessitate the use of iodine-based contrast agents, which could lead to post contrast acute kidney injury (pc-aki). sodium-glucose cotransporter 2 (sglt-2) inhibitors, as a class of oral antidiabetic medications, function by inhibiting sglt-2, preventing the reabsorption of filtered glucose by the kidneys and thereby increasing glucose excretion in urine. in recent years, a series of studies including empa-reg outcome, credence, dapa-ckd, declare-timi 58, and the canvas program have consistently demonstrated that sglt-2 inhibitors not only effectively improve renal function and slow the progression of chronic kidney disease (ckd), but also significantly reduce the risk of cardiovascular adverse events. nevertheless, due to their osmotic diuretic effect, sglt-2 inhibitors can lead to a reduction in renal blood volume within the early phase of application (within two weeks), temporarily augmenting the renal workload and resulting in a decrease in estimated glomerular filtration rate (egfr). consequently, there remains a need to ascertain the specific role of sglt-2 inhibitors in the prevention of pc-aki and provide evidence-based support for their application in this context.


Eligibility criteria:
inclusion criteria: * acs patients undergoing invasive treatment (pci or cag) * 18 \~ 80 years old adult patients * written informed consent provided exclusion criteria: * administration of any iodinated cm within 14 days before cag or pci * hepatic dysfunction (alt 3 times greater than upper normal limit) * thyreoid insufficiency * renal artery stenosis (unilateral \>70％ or bilateral stenosis\>50％) * known allergy to any of the study drugs or devices (iodinated cm, etc.) * pregnancy or lactation * contraindications for the use of sglt-2 inhibitors, such as severe renal insufficiency (egfr \<30 ml/min/1.73m2 or currently on dialysis), type 1 diabetes mellitus, severe infection, etc.) * any condition which might interfere with study compliance, or otherwise unsuitable for study participation as judged by the investigators
cognitive training in parkinson's disease

Conditions: Mental Competence

Summary: the study evaluates a computerized cognitive therapy in patients with parkinson's disease who have a mild cognitive impairment or mild dementia. the control group is "trained" using nintendo wii. the main outcome parameter is a neuropsychological evaluation.


Eligibility criteria:
inclusion criteria: * parkinson's disease and mild cognitive impairment (mci) or mild dementia exclusion criteria: * moderate or severe dementia, other pathologies of the brain, physical conditions that prevent the participation, unsufficient knowledge of german, pregnancy